| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... Cancer discovery 8 (4), 444-457, 2018 | 454 | 2018 |
| Treatment outcomes and tumor loss of heterozygosity in germline DNA repair–deficient prostate cancer M Annala, WJ Struss, EW Warner, K Beja, G Vandekerkhove, A Wong, ... European urology 72 (1), 34-42, 2017 | 213 | 2017 |
| Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer G Vandekerkhove, WJ Struss, M Annala, HML Kallio, D Khalaf, ... European urology 75 (4), 667-675, 2019 | 169 | 2019 |
| Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer G Vandekerkhove, T Todenhöfer, M Annala, WJ Struss, A Wong, K Beja, ... Clinical cancer research 23 (21), 6487-6497, 2017 | 146 | 2017 |
| Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma N Sundahl, G Vandekerkhove, K Decaestecker, A Meireson, ... European urology 75 (5), 707-711, 2019 | 103 | 2019 |
| Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer G Vandekerkhove, JM Lavoie, M Annala, AJ Murtha, N Sundahl, S Walz, ... Nature Communications 12 (1), 184, 2021 | 100 | 2021 |
| BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression E Warner, C Herberts, S Fu, S Yip, A Wong, G Wang, E Ritch, AJ Murtha, ... Clinical Cancer Research 27 (6), 1650-1662, 2021 | 67 | 2021 |
| Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer E Ritch, SYF Fu, C Herberts, G Wang, EW Warner, E Schönlau, ... Clinical Cancer Research 26 (5), 1114-1125, 2020 | 66 | 2020 |
| Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer C Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, H Xue, D Lin, ... European urology 78 (6), 834-844, 2020 | 64 | 2020 |
| Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition M Annala, S Taavitsainen, DJ Khalaf, G Vandekerkhove, K Beja, J Sipola, ... Clinical Cancer Research 27 (16), 4610-4623, 2021 | 51 | 2021 |
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018; 8: 444–457. doi: 10.1158/2159-8290 M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... CD-17-0937.[Abstract][CrossRef][Google Scholar], 0 | 50 | |
| A randomized phase II cross-over study of abiraterone+ prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). KN Chi, M Annala, K Sunderland, D Khalaf, D Finch, CD Oja, J Vergidis, ... Journal of Clinical Oncology 35 (15_suppl), 5002-5002, 2017 | 49 | 2017 |
| Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial M Annala, S Fu, JVW Bacon, J Sipola, N Iqbal, C Ferrario, M Ong, ... Annals of Oncology 32 (7), 896-905, 2021 | 48 | 2021 |
| Iris pigmentation as a quantitative trait: variation in populations of European, East Asian and South Asian ancestry and association with candidate gene polymorphisms M Edwards, D Cha, S Krithika, M Johnson, G Cook, EJ Parra Pigment cell & melanoma research 29 (2), 141-162, 2016 | 46 | 2016 |
| Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma ECP Chedgy, G Vandekerkhove, C Herberts, M Annala, AJ Donoghue, ... The Journal of pathology 246 (2), 244-253, 2018 | 43 | 2018 |
| Association study confirms the role of two OCA2 polymorphisms in normal skin pigmentation variation in East Asian populations K Eaton, M Edwards, S Krithika, G Cook, H Norton, EJ Parra American Journal of Human Biology 27 (4), 520-525, 2015 | 43 | 2015 |
| Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer V Genitsch, A Kollár, G Vandekerkhove, J Blarer, M Furrer, M Annala, ... Urologic Oncology: Seminars and Original Investigations 37 (11), 826-836, 2019 | 37 | 2019 |
| Phase 2 randomized cross-over trial of abiraterone+ prednisone (ABI+ P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC … D Khalaf, M Annala, DL Finch, CD Oja, J Vergidis, M Zulfiqar, ... Journal of Clinical Oncology 36 (15_suppl), 5015-5015, 2018 | 28 | 2018 |
| Frequent mutation of the FOXA1 untranslated region in prostate cancer M Annala, S Taavitsainen, G Vandekerkhove, JVW Bacon, K Beja, KN Chi, ... Communications biology 1 (1), 122, 2018 | 26 | 2018 |
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018; 8 (4): 444–57 M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... CD-17-0937.[Abstract][CrossRef][Google Scholar], 0 | 24 | |
Alexander WyattAssociate Professor, University of British ColumbiaVerified email at prostatecentre.com
